Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Micropeptide UEIS attenuates cGAS-STING-type I IFN signalling to repress anti-tumour immunity

ABSTRACT: Immune checkpoint blockade (ICB) has achieved remarkable success in cancer treatment; however, enhancing its efficacy remains a significant challenge. Selectively restoring tumour-induced immune deficiency within the tumour microenvironment is considered an ideal strategy for unleashing antitumour immunity without causing severe toxicity. Here, we describe an immunoregulatory micropeptide encoded by a long non-coding RNA (lncRNA) gene identified through comprehensive bioinformatic screening, which we designate as UEIS. UEIS was found to be upregulated in tumour-associated macrophages (TAMs) and to drive macrophages toward a pro-tumorigenic phenotype, thereby inhibiting antitumour T-cell immunity. Mechanistically, the expression of UEIS is induced by cGAS-STING-type I interferon (IFN) signalling at a relatively late stage following tumoral DNA stimulation. Thus, we identify the endogenous existence of a lncRNA-encoded micropeptide and reveal its inhibitory effect on cGAS-STING-type I IFN signalling via a feedback loop in TAMs. These findings highlight UEIS as a promising therapeutic target for cancer treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE299896 | GEO | 2026/04/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Micropeptide UEIS attenuates cGAS-STING-type I IFN signalling by forming a phase separation with TBK1 to repress anti-tumour immunity

Project description:Immune checkpoint blockade (ICB) has achieved remarkable success in cancer treatment; however, enhancing its efficacy remains a significant challenge. Selectively restoring tumour-induced immune deficiency within the tumour microenvironment is considered an ideal strategy for unleashing antitumour immunity without causing severe toxicity. Here, we describe an immunoregulatory micropeptide encoded by a long non-coding RNA (lncRNA) gene identified through comprehensive bioinformatic screening, which we designate as UEIS (USP30-AS1 encoded immune suppressor). UEIS was found to be upregulated in tumour-associated macrophages (TAMs) and to drive macrophages toward a pro-tumorigenic phenotype, thereby inhibiting antitumour T-cell immunity. Mechanistically, the expression of UEIS is induced by cGAS-STING-type I interferon (IFN) signalling at a relatively late stage following tumoral DNA stimulation. Subsequently, UEIS exerts a negative feedback regulation on the type I IFN signalling pathway by forming biomolecular condensates with TBK1. This interaction sequesters TBK1, thereby inhibiting its interaction with STING and consequently suppressing downstream signalling events. Intriguingly, both an intrinsically disordered region and an alpha helix at the extreme N-terminus of UEIS were found to be essential for its function. A peptide designed to disrupt UEIS-TBK1 condensation successfully inhibited UEIS function, leading to reduced tumour growth and increased response to ICB. Thus, we identify the endogenous existence of a lncRNA-encoded micropeptide and reveal its inhibitory effect on cGAS-STING-type I IFN signalling via a feedback loop in TAMs. These findings highlight UEIS as a promising therapeutic target for cancer treatment.

2026-05-25 | PXD078808 |

Micropeptide UEIS attenuates cGAS-STING-type I IFN signalling to repress anti-tumour immunity

Project description:Micropeptide UEIS attenuates cGAS-STING-type I IFN signalling to repress anti-tumour immunity

| PRJNA1277268 | ENA

ARF1 prevents aberrant type I IFN induction by regulating STING activation and recycling

Project description:Type I interferon (IFN) signalling is tightly controlled. Upon recognition of DNA by cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING) translocates along the endoplasmic reticulum (ER)-Golgi axis to induce IFN signalling. Afterwards, signal termination is achieved through autophagic degradation of STING, or STING recycling by retrograde COPI-mediated transport. Here we identify the GTPase ARF1 as a negative regulator of cGAS-STING signaling. Heterozygous ARF1 missense mutations cause a novel type I interferonopathy associated with enhanced IFN stimulated gene production. Expression of patient-derived, GTPase-defective, ARF1 in cell lines and primary cells results in increased cGAS-STING dependent type I IFN signalling. Mechanistically, mutated ARF1 both induces activation of cGAS by aberrant mitochondrial DNA, and promotes accumulation of active STING at the Golgi/ERGIC due to defective COPI retrograde transport. Our data establish ARF1 as a key factor in cGAS-STING homeostasis, which is required to maintain mitochondrial integrity and promote STING recycling.

2022-06-23 | MSV000089711 | MassIVE

Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways

Project description:The efficacy of stimulator of interferon genes (STING) agonists is compromised by various factors, primarily inefficient intracellular delivery, low/lack of endogenous STING expression in many tumours and a complex balance between tumour control and progression. Here, we report a universal STING mimic (uniSTING) based on a polymeric architecture. The uniSTING activates STING signalling in a range of mouse and human cell types, independent of endogenous STING expression, and selectively stimulates tumour control IRF3/IFN-I pathways, but not tumour progression NF-κB pathways. Intratumoural or systemic injection of uniSTING-mRNA via lipid nanoparticles (LNP) results in potent anti-tumour efficacy across established and advanced metastatic tumour models, including triple negative breast cancer, lung cancer, melanoma and orthotopic/metastatic liver malignancies. Furthermore, uniSTING displays an effective antitumour response superior to 2’3’-cGAMP and ADU-S100. By favouring IRF3/IFN-I activity over the pro-inflammatory NF-κB signalling pathway, uniSTING promotes dendritic cell maturation and antigen specific CD8+ T cell responses. Extracellular vesicles released from uniSTING-treated tumour cells further sensitise dendritic cells via exosome containing miRNAs that reduced the immunosuppressive Wnt2b and a combination of LNP-uniSTING-mRNA with α-Wnt2b antibodies synergistically inhibit tumour growth and prolong animal survival. Collectively, these results demonstrate the LNP-mediated delivery of uniSTING-mRNA as a strategy to overcome the current STING therapeutic barriers, particularly for the treatment of multiple cancer types in which STING is downregulated or absent.

2024-01-22 | GSE253724 | GEO

Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways

2024-01-24 | GSE253681 | GEO

A Cytotoxic T Cell Inspired Oncolytic Nanosystem Promotes Lytic Cell Death by Lipid Peroxidation And Elicits Antitumor Immune Responses

Project description:Lytic cell death triggers an antitumour immune response. However, cancer cells evade lytic cell death by several mechanisms. Moreover, a prolonged uncontrolled immune response conversely leads to T-cell exhaustion. Therefore, an oncolytic system capable of eliciting the immune response by dissolving cancer cells in a controlled manner is needed. Here, we establish a micro-scale cytotoxic T-cell-inspired oncolytic system (TIOs) to precisely lyse cancer cells by NIR-light-controlled lipid peroxidation. Our TIOs present antigen-based cell recognition, tumour-targeting and catalytic cell-lysis ability; thus, the TIOs induce oncolysis in vivo. We applied TIOs to antitumour therapies, which shows kinds of tumour models are cleared efficiently with negligible side-effects. Tumour regression is correlated with a T-cell based anti-tumour immune response and can be synergistic with anti-PD-1 therapy or STING activation. Our study provides new insights to design the oncolytic systems for antitumour immunity. Moreover, activation of STING can reverse T-cell exhaustion in oncolysis.

2023-09-05 | PXD044912 | Pride

Inhibiting macrophage-derived lactate transport restores cGAS-STING signaling and enhances anti-tumour immunity in glioblastoma

Project description:Glioblastoma (GBM) is a malignancy with a complex tumour microenvironment (TME) dominated by GBM stem cells (GSCs) and infiltrated by tumour-associated macrophages (TAMs) and exhibits aberrant metabolic pathways. Lactate is a critical glycolytic metabolite that promotes tumour progression; however, the mechanisms of lactate transport and lactylation in the TME of GBM remain elusive. Here we show that lactate is transported from TAMs to GSCs via MCT4–MCT1. TAMs provide lactate to GSCs, promoting GSC proliferation and inducing lactylation of the non-homologous end joining protein KU70 at lysine 317 (K317), which inhibits cGAS–STING signalling and remodels the immunosuppressive TME. Inhibition of lactate transport or targeting the lactylation of KU70, in combination with the immune checkpoint blockade, demonstrates additive therapeutic benefits in immunocompetent xenograft models. This study unveils TAM-derived lactate and lactylation as critical regulators in GSCs to enforce an immunosuppressive microenvironment, opening avenues for developing combinatorial therapy for GBM.

2024-06-01 | GSE266884 | GEO

HDAC6 deacetylates TRIM56 to negatively regulate cGAS-mediated type I interferon response

Project description:Histone deacetylase 6 (HDAC6), a member of the class IIB HDAC family, has distinct biological functions through primarily deacetylating cytoplasmic non-histone proteins. However, its regulatory role in response to DNA virus infection remains elusive. Herein, we find that HDAC6 is a negative regulator of the cGAS-STING signaling pathway. HDAC6 deacetylase activity is increased in the early stage of Herpes simplex virus 1 (HSV-1) infection, and HDAC6 deficiency or inhibition of its deacetylase activity markedly promotes the activation of the cGAS-STING axis, resulting in increased expression of type I interferon (IFN) and a decrease in HSV-1 infection. Consistently, the Hdac6-/- mice exhibit increased resistance to HSV-1 infection and HSV-1 induced encephalitis (HSE). The HDAC6-interactome and Acetylome proteomics assays reveal that HDAC6 interacts with and deacetylates Tripartite motif protein 56 (TRIM56) at K110 within the B-box1 domain, leading to the reduced monoubiquitination and DNA binding of cGAS by TRIM56. In addition, acetylation of TRIM56 K110 is key to its binding to HDAC6 and regulating the IFN response, as evidenced by the opposing outcomes observed upon overexpressing TRIM56 K110Q and K110R on the cGAS-STING axis. Overexpression of TRIM56 K110Q further enhances protection against HSV-1 infection and HSE pathogenesis in mice, alongside increased activation of the cGAS-STING-IFN axis. Interestingly, TRIM56 displays species-specific K110, which differentially regulates the IFN response in humans and mice. Furthermore, HDAC6 accumulates in the cytoplasm and is phosphorylated by the viral protein US3, which increases its deacetylase activity and interaction with TRIM56 in the early infection stage. Together, our findings disclose that HDAC6 negatively regulates cGAS activation through TRIM56 deacetylation, suggesting a potential antiviral strategy by inhibiting HDAC6 activity.

2024-12-21 | PXD046808 | Pride

An HIV protein mediates immune evasion by targeting cGAS–STING signaling

Project description:The cyclic GMP-AMP synthase (cGAS) recognizes Y-form cDNA of HIV-1 and initiate the antiviral immune response through cGAS–STING–TBK1–IRF3–type I IFN (IFN-I) signaling cascade. HIV-1 uses several strategies to interfere with the host immune molecules and mediate immune evasion. However, the potential role of HIV-1 proteins in cGAS–STING signaling remains unclear. Here we report that the HIV-1 protein p6 suppresses HIV-1-stimulated expression of IFN-I and promotes the immune evasion. Mechanistically, p6 bound with STING and inhibited the activation of STING and the interaction between STING and TBK1. Moreover, the glutamylation of p6 at Glu6 residue inhibited the interaction between STING and TRIM32 or AMFR, which subsequently suppressed the K27- and K63-linked polyubiquitination of STING at Lys337, therefore inhibited STING activation and type I IFN production, while the mutation of Glu6 residue lost the inhibitory effect. However, CoCl2, an agonist for cytosolic carboxypeptidases (CCPs), counteracted the glutamylation of Glu6 residue of p6 and promoted IFN-I production to block the immune evasion of HIV-1. These findings not only reveal a previously unknown mechanism through which an HIV-1 protein mediate immune evasion, but also provide a new therapeutic drug candidate to treat HIV-1 infection.

2021-11-25 | GSE189384 | GEO

Interferon Signaling After TBI in Aged Mice

Project description:Type I Interferons (IFN-I) contribute to the neuropathology of traumatic brain injury (TBI) and age-related neurodegenerative disease, where Cyclic GMP-AMP Synthase (cGAS) and the Stimulator of Interferon Genes (STING) pathway are implicated as key inducers of IFN-I responses. This study evaluated cGAS/STING activation, IFN-I signaling and neuroinflammation in the cortex and hippocampus of young and aged C57Bl/6 male mice, 24 hrs after controlled cortical impact injury. TBI increased expression of transcripts related to IFN-I signaling and activation of cGAS in the injured cortex of aged mice compared to younger mice. These observations were confirmed by RT-PCR, western blotting and phosphorylation/activation of STAT1, a downstream IFN-I effector molecule

2021-08-20 | GSE180811 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data